Bristol-Myers Squibb to Present at Goldman Sachs Healthcare CEOs Unscripted Conference

NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) will present at the Goldman Sachs Healthcare CEOs Unscripted conference on Thursday, January 5, 2012, in New York. Elliott Sigal, executive vice president, chief scientific officer & president, R&D, will participate in a Q&A session about the company at 4 p.m. EST.

Investors and the general public are invited to listen to a live webcast of the presentation at http://investor.bms.com.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.



CONTACT:

Bristol-Myers Squibb
Media: Jennifer Fron Mauer, 609-252-6579
[email protected]
or
Investors: John Elicker, 609-252-4611
[email protected]

KEYWORDS:   United States  North America  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.